Outpatient Full Closed-Loop Trial Using An Open-Source Remote Monitoring and Artificial Pancreas Platform

FABRICIO GARELLI; NICOLÁS ROSALES; EMILIA FUSHIMI; DELFINA ARAMBARRI; CECILIA SERAFINI; HERNÁN DE BATTISTA; RICARDO SANCHEZ PEÑA; JULIA GARCÍA ARABEHETY; JAVIER GIUNTA; LUIS GROSEMBACHER

Conferencia; 21st Annual Diabetes Technology Meeting.; 2021

DTS

Objective:The first artificial pancreas (AP) ambulatory clinical trial in Argentina conducted in March 2021 in the COVID-19 pandemic context is reported. The main objective of this trial was to evaluate the feasibility of running advanced full closed-loop (FCL) algorithms for glycemic control in an own and free platform developed by the team at UNLP from open-source resources (www.insumate.com.ar). Method:The ARG algorithm, a FCL algorithm previously evaluated in-vivo [1], was implemented in InsuMate-AP. This platform was then connected to Dexcom G6 CGMs and Accu-Chek Spirit Combo insulin pumps. After configuring conventional open-loop (OL) treatment in the pumps, five adults with Type 1 Diabetes Mellitus completed one week of an ambulatory clinical trial, consisting in 3 days of OL treatment followed by 3 days of FCL glycemic control (i.e., without delivering meal priming insulin boluses). The participants performed regular activities in a hotel, including networking, eating without carbohydrates counting and extensive walking (3-5 km) around the neighborhood.Result:The last 24 hours of each phase were compared, finding a 25,3% increase in time in range (TIR, 70 mg/dl